Status:

COMPLETED

New-onset Severe Headache After Covid-19 Vaccine

Lead Sponsor:

Oslo University Hospital

Collaborating Sponsors:

St. Olavs Hospital

University Hospital, Akershus

Conditions:

Headache

Migraine

Eligibility:

All Genders

18+ years

Brief Summary

Hypotheses: 1. Severe new-onset headache after Covid-19 vaccine occur in a minor subset of vaccinated individuals. 2. Immunological reactivity with activation of trigeminal nociceptors can be among t...

Detailed Description

Study Design: Prospective observational multi-center study Cohort study of patients with new-onset severe headache after Covid-19 vaccine. Patients referred to the participating headache clinics for ...

Eligibility Criteria

Inclusion

  • IInclusion criteria:
  • Patients aged ≥ 18 years with new onset severe headache or severe worsening of pre-existing headache within one week after Covid vaccination and has not resolved within 3 weeks.
  • Inclusion within 12 months after symptom onset.
  • Informed written consent signed by the patient.
  • Exclusion criteria:
  • • Patients not available for follow-up assessments (e.g. non-resident).

Exclusion

    Key Trial Info

    Start Date :

    January 1 2022

    Trial Type :

    OBSERVATIONAL

    Allocation :

    ACTUAL

    End Date :

    December 31 2023

    Estimated Enrollment :

    63 Patients enrolled

    Trial Details

    Trial ID

    NCT05235776

    Start Date

    January 1 2022

    End Date

    December 31 2023

    Last Update

    July 3 2024

    Active Locations (10)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 3 (10 locations)

    1

    Medi3

    Ålesund, Norway

    2

    Hodepineklinikkken Bergen

    Bergen, Norway

    3

    Anub Mathew Thomas

    Drammen, Norway

    4

    Helsa Fonna Trust

    Haugesund, Norway